Armata Pharmaceuticals (ARMP) Net Cash Flow (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Net Cash Flow data on file, last reported at -$5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 325.57% year-over-year to -$5.2 million; the trailing twelve-month figure through Mar 2026 stood at -$8.2 million (up 68.76% YoY), and the FY2025 full-year result was -$693000.0, up 84.5% from the prior year.
• Net Cash Flow rose to -$5.2 million in Q1 2026, from -$6.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $40.9 million in Q1 2022 to a low of -$12.6 million in Q2 2023.
• A 5-year average of -$153764.7 and a median of -$7.4 million in 2025 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 219.23% in 2022, while the deepest fall reached 488.93% in 2022.
• Tracing ARMP's Net Cash Flow over 5 years: stood at -$10.5 million in 2022, then dropped by 0.09% to -$10.5 million in 2023, then advanced by 25.51% to -$7.8 million in 2024, then increased by 22.7% to -$6.1 million in 2025, then gained by 14.24% to -$5.2 million in 2026.
• Business Quant data shows ARMP's Net Cash Flow at -$5.2 million in Q1 2026, -$6.1 million in Q4 2025, and $10.4 million in Q3 2025.